WO2003015781A1 - Novel antidiabetic pharmaceutical compositions - Google Patents

Novel antidiabetic pharmaceutical compositions Download PDF

Info

Publication number
WO2003015781A1
WO2003015781A1 PCT/JP2002/008276 JP0208276W WO03015781A1 WO 2003015781 A1 WO2003015781 A1 WO 2003015781A1 JP 0208276 W JP0208276 W JP 0208276W WO 03015781 A1 WO03015781 A1 WO 03015781A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
pharmaceutical compositions
bonded
heteroaryl
novel antidiabetic
Prior art date
Application number
PCT/JP2002/008276
Other languages
French (fr)
Japanese (ja)
Inventor
Toshihiko Fujiwara
Shigeru Ushiyama
Tomio Kimura
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Publication of WO2003015781A1 publication Critical patent/WO2003015781A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Pharmaceutical compositions for the prevention or treatment of diabetes, containing as the active ingredient compounds represented by the general formula (I), or pharmacologically acceptable salts, esters, or other derivatives thereof: (I) wherein A is benzene, pyridine, pyridazine, pyrimidine, pyrrole, furan, thiophene, pyrazole, imidazole, isoxazole, or isothiazole, each being optionally substituted; R1 is aryl or heteroaryl, each being optionally substituted; R2 is optionally substituted nitrogenous heteroaryl; and R3 is a mono- or poly-cyclic nitrogenous heterocycle which may be substituted, with the proviso that the A-constituent atoms to which R1 and R3 bonded are each adjacent to the A-constituent atom to which R2 is bonded.
PCT/JP2002/008276 2001-08-15 2002-08-14 Novel antidiabetic pharmaceutical compositions WO2003015781A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001246344 2001-08-15
JP2001-246344 2001-08-15

Publications (1)

Publication Number Publication Date
WO2003015781A1 true WO2003015781A1 (en) 2003-02-27

Family

ID=19075908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008276 WO2003015781A1 (en) 2001-08-15 2002-08-14 Novel antidiabetic pharmaceutical compositions

Country Status (1)

Country Link
WO (1) WO2003015781A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009592A1 (en) * 2002-07-19 2004-01-29 Sankyo Company, Limited Bicyclic unsaturated tertiary amine compound
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2011042389A3 (en) * 2009-10-09 2012-08-16 Bayer Cropscience Ag Phenylpyri(mi)dinylazoles and their use as fungicides
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070711A2 (en) * 1999-07-21 2001-01-24 Sankyo Company Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
WO2002057265A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited Compounds substituted with bicyclic amino groups
WO2002057264A1 (en) * 2001-01-22 2002-07-25 Sankyo Company Limited Pyrrole derivates for treating cytokine mediated diseases
WO2002057255A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited 4- or 5-substituted pyrrole derivatives
JP2002284779A (en) * 2001-01-18 2002-10-03 Sankyo Co Ltd Medicine containing heteroaryl-substituted pyrrole derivative

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070711A2 (en) * 1999-07-21 2001-01-24 Sankyo Company Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
JP2002284779A (en) * 2001-01-18 2002-10-03 Sankyo Co Ltd Medicine containing heteroaryl-substituted pyrrole derivative
WO2002057265A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited Compounds substituted with bicyclic amino groups
WO2002057264A1 (en) * 2001-01-22 2002-07-25 Sankyo Company Limited Pyrrole derivates for treating cytokine mediated diseases
WO2002057255A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited 4- or 5-substituted pyrrole derivatives

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009592A1 (en) * 2002-07-19 2004-01-29 Sankyo Company, Limited Bicyclic unsaturated tertiary amine compound
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2011042389A3 (en) * 2009-10-09 2012-08-16 Bayer Cropscience Ag Phenylpyri(mi)dinylazoles and their use as fungicides
JP2013507334A (en) * 2009-10-09 2013-03-04 バイエル・クロップサイエンス・アーゲー Phenylpyri (mi) dinirazoles
EP2784071A1 (en) * 2009-10-09 2014-10-01 Bayer CropScience AG 3-phenyl-4-pyri(mi)dinyl-1h-pyrazoles and their use as fungicides
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same

Similar Documents

Publication Publication Date Title
WO2003011880A1 (en) Glucopyrano syloxybenzyl benzene derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
WO2007137008A3 (en) Compounds for the treatment of metabolic disorders
EP1598349A4 (en) Novel 2-pyridinecarboxamide derivatives
IL164487A0 (en) 3-Heteroaryl substituted 5-methyloxymethyl isoxazolines used as herbicides
WO2007087505A3 (en) Compounds for the treatment of metabolic disorders
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
CA2565660A1 (en) Ortho substituted aryl or heteroaryl amide compounds
EP1698628A4 (en) Hydroxypyrimidinone derivative having hiv integrase inhibitory activity
CA2626767A1 (en) Heterocyclic substituted pyridine derivatives and antifungal agent containing same
NO20054791L (en) Compounds for the treatment of metabolic disorders
WO2006127426A3 (en) Insecticidal substituted benzylamino heterocyclic and heteroaryl derivatives
WO2008111441A1 (en) Pharmaceutical composition
WO2004073611A3 (en) Compounds for the treatment of metabolic disorders
HK1083460A1 (en) Compounds for the treatment of metabolic disorders
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
EP1642880A4 (en) Hsp90 family protein inhibitors
EP1813270A4 (en) Hsp90 family protein inhibitors
CA2336412A1 (en) Medicament for treatment of diabetes
WO2008153042A1 (en) Anti-tumor agent
WO2004093806A3 (en) Compounds for the treatment of metabolic disorders
WO2007080270A3 (en) New cholest-4-en-3-one oxime derivatives, pharmaceutical compositions comprising them, and preparation process
NO20055695L (en) Tiadiazine compounds and their use as positive AMPA receptor modulators
WO2007093292A3 (en) Insecticidal substituted amino heterocyclic and heteroaryl derivatives
WO2003015781A1 (en) Novel antidiabetic pharmaceutical compositions
EP1361225A4 (en) Compounds substituted with bicyclic amino groups

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP